In January 2026, Jeff La Marca received a prescription for Zepbound, a popular weight loss medication, but faced a $750 monthly cost he could not afford. When Medicare launched an 18-month pilot program in early 2026 offering GLP-1 drugs for just $50 a month to some enrollees, La Marca believed he had found a solution to his financial burden. The program, known as Bridge, provides significant savings but only applies to individuals using GLP-1 medications exclusively for weight loss. Patients who take these drugs for other medical conditions, such as diabetes or heart disease, do not qualify for the discounted rate. This restriction means that many sicker patients, who may benefit most from the medication, are excluded from the cost-saving initiative. Why the Weight-Only Rule Exists Medicare officials designed the Bridge program to test coverage for obesity treatment specifically, separating it from existing diabetes benefits.
The agency states that GLP-1 drugs for weight loss are not currently covered under standard Medicare Part D, necessitating a separate pilot. By limiting the discount to weight-only use, Medicare aims to gather data on demand and outcomes without interfering with established chronic disease management programs. Critics argue this creates an unfair divide between patients based on their diagnosis rather than medical need.
Although La Marca uses Zepbound for weight loss and technically qualifies, he remains concerned about the program's stability and future availability. The 18-month timeline creates uncertainty for long-term treatment planning. Healthcare providers note that patients often require GLP-1 therapy beyond a year and worry about abrupt cost increases after the pilot ends. Some clinicians report that eligible patients still struggle with access due to prior authorization hurdles or pharmacy participation limits. What Happens When the Pilot Ends? When the Bridge program concludes in mid-2027, participants may face a return to full drug pricing unless Medicare extends the initiative or incorporates GLP-1 coverage into standard benefits. Advocacy groups are urging Congress to pass legislation ensuring affordable access regardless of indication.
Without policy changes, many patients could be forced to discontinue effective treatment due to cost, potentially worsening health outcomes and increasing long-term healthcare spending. Frequently Asked Questions Who qualifies for the $50 monthly GLP-1 price under Medicare's Bridge program? Only Medicare enrollees who use GLP-1 medications solely for weight loss qualify for the $50 monthly price; those using the drugs for diabetes, heart disease, or other conditions are excluded. Is the Bridge program available to all Medicare beneficiaries? No, the program is limited to certain enrollees in the pilot, and eligibility also depends on the specific use of the medication being restricted to weight loss purposes. What happens to patients after the 18-month pilot ends? After the program ends in mid-2027, participants may lose the discounted rate and face higher costs unless Medicare extends the program or changes national coverage policies for GLP-1 drugs.